Mild Cognitive Impairment Clinical Trial
Official title:
Community-based, Buddy-supported Exercise in Patients With MCI: a Pilot Trial
NCT number | NCT01561820 |
Other study ID # | IRB00018495 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2011 |
Est. completion date | December 2012 |
Verified date | September 2019 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a small pilot trial of a 5 month aerobic exercise intervention in participants with MCI (n=20) to begin to compare the effects of randomization to use an exercise buddy or to exercise without an assigned buddy. The investigators hypothesize that participants with MCI who exercise with a buddy will have higher adherence to the protocol and greater improvement in 400 meter walk time.
Status | Completed |
Enrollment | 15 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: Participants: - Age 60 and up - Montreal Cognitive Assessment (MoCA) score 16-28 - CDR= 0.5 with memory box at least 0.5. - Have a person (study partner) who can answer questions about their cognition for the CDR, FAQ and NPI-Q. This should be the same person who will come to all clinic visits whenever possible. This person can be called to answer these questions if unable to come into the clinic. - Sedentary for past 3 months (< 45 min /wk of exercise, including walking) - Able to walk 400 meters in < 15 min without assistance - Willing to exercise 4 days a week at Body Check at CompRehab - Physician approval for participation in the exercise intervention Buddy: - No report of memory problem - MoCA score > 24 if > HS education; > 23 if 9-12 years; > 22 if ,< 9 years of education Exclusion Criteria: Due to Cognitive Confounders: - Uncontrolled depression (PHQ-9 > 10) - Schizophrenia or bipolar disorder - Parkinson's disease - Hachinski ischemic index > 4 - Daily use of highly anticholinergic medications (such as amitriptyline, diphenhydramine, scopolamine, etc) or benzodiazepines - Use of stable dose of Cholinesterase inhibitors will be permitted. Must be on a stable dose for 4 weeks. - Non-English speaking (as we are unable to administer the cognitive tests in languages other than English for this pilot) - Vitamin B12 deficiency - Uncontrolled hypothyroidism as measured by TSH blood test Due to increased risk of or low likelihood of compliance with the exercise program: - Active ischemic heart disease or angina - symptomatic heart failure - stroke - screening blood pressure SBP > 170 or < 90; DBP > 100 or < 45 - Parkinson's disease or other neurologic disorder that might make exercise on a treadmill or bike unsafe - Current or planned treatment for cancer - peripheral artery disease that limits exercise capacity - Severe respiratory-disease (e.g., COPD) that limits exercise capacity - Severe arthritis that limits exercise capacity - Serious conduction disorder, uncontrolled arrhythmia, or new Q waves or ST-segment depressions (> 3 mm) on ECG - Severe anemia (Hgb < 8) - Diagnosis of Diabetes and on medication - Drinks more than 14 alcoholic drinks per week - Dependent on a cane, walker or other device that would inhibit then from using a treadmill |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest Baptist Health | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Adherence (number of sessions attended and exercise duration in targeted heart rate zone) | This is a pilot study with the principle outcome measures related to recruitment and retention of participants with MCI and buddies and adherence to the protocol. We are specifically interested in: Time to recruit 20 participants % of participants who identify their own buddy Number of community volunteers to be buddies over the recruitment period Retention at 3- and 5- months Adherence (number of exercise sessions attended, exercise duration in targeted HR zone) |
4 times a week for 5 months (each exercise session) | |
Secondary | Change in score on Digit Symbol Coding Test | Baseline 3 months and 5 months | ||
Secondary | Change in 400m walk time (from randomization to 5 months) | Baseline, 3 months and 5 months | ||
Secondary | Change in Trail Making Test part B score | Baseline and 5 months | ||
Secondary | change in memory, measured by Rey AVLT delayed recall score, at 5 months | baseline and 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04513106 -
Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial
|
N/A | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Active, not recruiting |
NCT03167840 -
Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment
|
N/A | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Not yet recruiting |
NCT05041790 -
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
|
Phase 4 | |
Recruiting |
NCT04121156 -
High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT03605381 -
MORbidity PRevalence Estimate In StrokE
|
||
Completed |
NCT02774083 -
Cognitive Training Using Feuerstein Instrumental Enrichment
|
N/A | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Enrolling by invitation |
NCT06023446 -
Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
|
||
Completed |
NCT04567745 -
Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
|
Phase 1 | |
Recruiting |
NCT05579236 -
Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
|
||
Completed |
NCT03583879 -
Using Gait Robotics to Improve Symptoms of Parkinson's Disease
|
N/A | |
Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Active, not recruiting |
NCT05204940 -
Longitudinal Observational Biomarker Study
|
||
Recruiting |
NCT02663531 -
Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease
|
N/A | |
Recruiting |
NCT06150352 -
Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
|
||
Recruiting |
NCT03507192 -
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
|
N/A |